Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Open access
Karlovich, Chris, Goldman, Jonathan W., Sun, Jong-Mu, Mann, Elaina, Sequist, Lecia V., Konopa, Krzysztof, Wen, Wei, Angenendt, Philipp, Horn, Leora, Spigel, David, Soria, Jean-Charles, Solomon, Benjamin, Camidge, D. Ross, Gadgeel, Shirish, Paweletz, Cloud, Wu, Lin, Chien, Sean, O'Donnell, Patrick, Matheny, Shannon, Despain, Darrin, Rolfe, Lindsey, Raponi, Mitch, Allen, Andrew R., Park, Keunchil, Wakelee, Heather·2016·Clinical Cancer Research

Abstract

Purpose: The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored. We investigated the detection of EGFR activating and T790M mutations in matched tumor tissue and plasma, mostly from patients with acquired resistance to first-generation EGFR inhibitors. Experimental Design: Samples were obtained from two studies, an observational study and a phase I trial of rociletinib, a mutant-selective inhibitor of EGFR that targets both activating mutations and T790M. Plasma testing was performed with the cobas EGFR plasma test and BEAMing. Results: The positive percent agreement (PPA) between cobas plasma and tumor results was 73% (55/75) for activating mutations and 64% (21/33) for T790M. The PPA between BEAMing plasma and tumor results was 82% (49/60) for activating mutations and 73% (33/45) for T790M. Presence of extrathoracic (M1b) versus intrathoracic (M1a/M0) disease was found to be strongly associated with ability to identify EGFR mutations in plasma (P < 0.001). Rociletinib objective response rates (ORR) were 52% [95% confidence interval (CI), 31 – 74%] for cobas tumor T790M-positive and 44% (95% CI, 25 – 63%) for BEAMing plasma T790M-positive patients. A drop in plasma-mutant EGFR levels to ≤10 molecules/mL was seen by day 21 of treatment in 7 of 8 patients with documented partial response. Conclusions: These findings suggest the cobas and BEAMing plasma tests can be useful tools for noninvasive assessment and monitoring of the T790M resistance mutation in NSCLC, and could complement tumor testing by identifying T790M mutations missed because of tumor heterogeneity or biopsy inadequacy. Clin Cancer Res; 22(10); 2386–95. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1260

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 179

Metadata

Authors
Karlovich, C., Goldman, J. W., Sun, J.-M., Mann, E., Sequist, L. V., Konopa, K., Wen, W., Angenendt, P., Horn, L., Spigel, D., Soria, J.-C., Solomon, B., Camidge, D. R., Gadgeel, S., Paweletz, C., Wu, L., Chien, S., O'Donnell, P., Matheny, S., Despain, D., Rolfe, L., Raponi, M., Allen, A. R., Park, K., & Wakelee, H.
Venue
Clinical Cancer Research
Published
2016-05-12
Volume
22
Issue
10
Pages
2386-2395
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2231363008
Cited by
179
References
14
FWCI
31.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1260
The paper
Karlovich, C., Goldman, J. W., Sun, J.-M., Mann, E., Sequist, L. V., Konopa, K., Wen, W., Angenendt, P., Horn, L., Spigel, D., Soria, J.-C., Solomon, B., Camidge, D. R., Gadgeel, S., Paweletz, C., Wu, L., Chien, S., O'Donnell, P., Matheny, S., . . . Wakelee, H. (2016). Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.